Semisynthetic analogues of toxiferine i and their pharmacological properties at α7 nAChRs, Muscle-Type nAChRs, and the allosteric binding site of muscarinic M2 receptors

Journal of Natural Products

Volumn 77, Issue 9, 2014, Pages 2006-2013

  Zlotos, Darius P ^a   Tränkle, Christian ^b   Holzgrabe, Ulrike ^c   Gündisch, Daniela ^d   Jensen, Anders A ^e  

^a German University in Cairo   (Egypt)

^b UNIVERSITY OF BONN   (Germany)

^c UNIVERSITY OF WÜRZBURG   (Germany)

^d UNIVERSITY OF HAWAII AT HILO   (United States)

^e UNIVERSITY OF COPENHAGEN   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

4,4' DI(4 NITROBENZYL) 19,20,19',20' TETRAHYDRO 18' DEOXYBISNORTOXIFERINIUM I DIBROMIDE; 4,4' DI(4 NITROBENZYL) 19,20,19',20' TETRAHYDRO 18,18' DIDEOXYBISNORTOXIFERINIUM I DIBROMIDE; 4,4' DIALLYL 19,20,19',20' TETRAHYDRO 18' DEOXYBISNORTOXIFERINIUM I DIBROMIDE; 4,4' DIALLYL 19,20,19',20' TETRAHYDRO 18,18' DIDEOXYBISNORTOXIFERINIUM I DIBROMIDE; 4,4' DIMETHYL 19,20,19',20' TETRAHYDRO 18' DEOXYBISNORTOXIFERINIUM I DIIODIDE; 4,4' DIMETHYL 19,20,19',20' TETRAHYDRO 18,18' DIDEOXYBISNORTOXIFERINIUM I DIIODIDE; ALCURONIUM; BUNGAROTOXIN RECEPTOR; MUSCARINIC M2 RECEPTOR; MUSCARINIC M2 RECEPTOR ANTAGONIST; NICOTINIC RECEPTOR; NICOTINIC RECEPTOR BLOCKING AGENT; TOXIFERINE; TOXIFERINE I DERIVATIVE; UNCLASSIFIED DRUG; ALKALOID; LIGAND;

ANIMAL CELL; ARTICLE; BINDING AFFINITY; CHEMICAL BOND; CHEMICAL MODIFICATION; CONTROLLED STUDY; DRUG BINDING SITE; DRUG DESIGN; DRUG POTENCY; DRUG RECEPTOR BINDING; DRUG SELECTIVITY; DRUG STRUCTURE; DRUG SYNTHESIS; IC50; LIGAND BINDING; NEUROMUSCULAR BLOCKING; NONHUMAN; RECEPTOR AFFINITY; RECEPTOR BINDING ASSAY; ANALOGS AND DERIVATIVES; BINDING SITE; CHEMICAL STRUCTURE; CHEMISTRY; HUMAN; METABOLISM; MUSCLE; NUCLEAR MAGNETIC RESONANCE; SYNTHESIS;

ALKALOIDS; ALLOSTERIC SITE; ALPHA7 NICOTINIC ACETYLCHOLINE RECEPTOR; HUMANS; LIGANDS; MOLECULAR STRUCTURE; MUSCLES; NICOTINIC ANTAGONISTS; NUCLEAR MAGNETIC RESONANCE, BIOMOLECULAR; RECEPTOR, MUSCARINIC M2; TOXIFERINE;

EID: 84908611138     PISSN: 01633864     EISSN: 15206025     Source Type: Journal    
DOI: 10.1021/np500259j     Document Type: Article

References (37)

1. Jensen, A. A.; Frølund, B.; Liljefors, T.; Krogsgaard-Larsen, P. J. Med. Chem. 2005, 48, 4705-4745
2. Levin, E. D. Nicotinic Receptors in the Nervous System; CRC Press: Boca Raton, FL, 2002.
3. Cassels, B. K.; Bermudez, I.; Dajas, F.; Abin-Carriquiry, J. A.; Wonnacott, S. Drug Discovery Today 2006, 10, 1657-1665
4. Papke, R. L. Biochem. Pharmacol. 2014, 89, 1-11
5. Romanelli, M. N.; Gualtieri, F. Med. Res. Rev. 2003, 23, 393-426
6. Bunnelle, W. H.; Dart, M. J.; Schrimpf, M. R. Curr. Top. Med. Chem. 2004, 4, 299-334
7. Posados, I.; López-Hernández, B.; Cena, V. Curr. Neuropharmacol. 2013, 11, 298-314
8. Prochaska, J. J.; Das, S.; Benowitz, N. L. Br. Med. J. 2013, 347, f5198
9. Young, J. M.; Shytle, R. D.; Sanberg, P. R.; George, T. P. Clin. Ther. 2001, 23, 532-565
10. Shytle, R. D.; Silver, A. A.; Lukas, R. J.; Newman, M. B.; Sheehan, D. V.; Sanberg, P. R. Mol. Psychiatry. 2002, 7, 525-535
11. Papke, R. L.; Bencherif, M.; Lippiello, P. Neurosci. Lett. 1996, 213, 201-204
12. Horenstein, N. A.; Leonik, F. M.; Papke, R. L. Mol. Pharmacol. 2008, 74, 1496-1511
13. Meyer, E.; Kuryatov, A.; Gerzanich, V.; Lindstrom, J.; Papke, R. L. J. Pharmacol. Exp. Ther. 1998, 287, 918-925
14. Jensen, A. A.; Zlotos, D. P.; Liljefors, T. J. Med. Chem. 2007, 50, 4616-4629
15. Zlotos, D. P.; Gündisch, D.; Ferraro, S.; Tilotta, M. C.; Stiefl, N.; Baumann, K. Bioorg. Med. Chem. 2004, 12, 6277-6285
16. Zlotos, D. P.; Buller, S.; Tränkle, C.; Mohr, K. Bioorg. Med. Chem. Lett. 2000, 10, 2529-2532
17. Zlotos, D. P.; Buller, S.; Stiefl, N.; Baumann, K.; Mohr, K. J. Med. Chem. 2004, 47, 3561-3571
18. Da Silva, B. A.; de Araujo Filho, A. P.; Mukherjee, R.; Chiappeta, De A. Phytother. Res. 1993, 7, 419-424
19. Massiot, G.; Thepenier, P.; Jacquier, M. J.; Le-Men Olivier, L.; Delaude, C. Phytochemistry 1992, 31, 2873-2876
20. Bernauer, K.; Berlage, D.; von Philipsborn, W.; Schmid, H.; Karrer, P. Helv. Chim. Acta 1958, 41, 2293-2308
21. Boekelheide, V.; Ceder, O.; Crabb, T.; Kawazoe, Y.; Knowles, R. N. Tetrahedron Lett. 1960, 26, 1-4
22. Zlotos, D. P. J. Nat. Prod. 2000, 63, 864-865
23. Zlotos, D. P. J. Nat. Prod. 2003, 66, 119-120
24. Zlotos, D. P. Eur. J. Org. Chem. 2004, 2375-2380
25. Tridant V.1.1.2; Wavefunction, Inc.: Irvine, CA, USA, 2006.
26. Tränkle, C.; Kostenis, E.; Burgmer, U.; Mohr, K. J. Pharmacol. Exp. Ther. 1996, 279, 926-933
27. Tränkle, C.; Dittmann, A.; Schulz, U.; Weyand, O.; Buller, S.; Jöhren, K.; Heller, E.; Birdsall, N. J.; Holzgrabe, U.; Ellis, J.; Höltje, H. D.; Mohr, K. Mol. Pharmacol. 2005, 68, 1597-1610
28. Tränkle, C.; Mies-Klomfass, E.; Botero, C. H. M.; Holzgrabe, U.; Mohr, K. Mol. Pharmacol. 1998, 54, 139-145
29. Maass, A.; Mohr, K. Eur. J. Pharmacol. 1996, 305, 231-234
30. Bock, A.; Merten, N.; Schrage, R.; Dallanoce, C.; Bätz, J.; Klöckner, J.; Schmitz, J.; Matera, C.; Simon, K.; Kebig, A.; Peters, L.; Müller, A.; Schrobang-Ley, J.; Tränkle, C.; Hoffmann, C.; De Amici, M.; Holzgrabe, U.; Kostenis, E.; Mohr, K. Nat. Commun. 2012, 3, 1044
31. Boller, A.; Els, H.; Furst, A. U.S. Patent 3080373, 1961.
32. Feuerbach, D.; Lingenhöhl, K.; Dobbins, P.; Mosbacher, J.; Corbett, N.; Nozulak, J.; Hoyer, D. Neuropharmacology 2005, 48, 215-227
33. Armishaw, C.; Jensen, A. A.; Balle, T.; Clark, R. J.; Harpsøe, K.; Skonberg, C.; Liljefors, T.; Strømgaard, K. J. Biol. Chem. 2009, 284, 9498-9512
34. Kostenis, E.; Mohr, K. Trends Pharmacol. Sci. 1996, 17, 280-283
35. Tränkle, C.; Andresen, I.; Lambrecht, G.; Mohr, K. Mol. Pharmacol. 1998, 53, 304-312
36. Fang, L.; Jumpertz, S.; Zhang, Y.; Appenroth, D.; Fleck, C.; Mohr, K.; Tränkle, C.; Decker, M. J. Med. Chem. 2010, 53, 2094-20103
37. DeBlasi, A.; OReilly, K.; Motulsky, H. J. Trends Pharmacol. Sci. 1989, 10, 227-229